IOL Chemicals & Pharmaceuticals Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r58one1ro3vo8qcjti5ycya2.pdf

Key Takeaways


Segment Performance

SegmentTrendCommentary
Pharmaceuticals▬ ResilientEBIT margin of 13.22%, supported by stable ibuprofen pricing at $10–$11, lower competition, and new product launches in the US and international markets.
Specialty Chemicals▼ WeakEBIT margin of just 0.48% driven by inventory overhang, poor spreads, and a mismatch between input costs (alcohol, Acetic Acid) and final chemical prices, especially Ethyl Acetate. Volatility from Chinese players added pressure.
Mahajan: "But all these are correspondent with the reduction in raw material prices also."

Non-Ibuprofen Growth & Export Push

Singh: "Existing revenue is coming from all these product plants. The difference is that now all these products also got approved by ANVISA, Brazil. With this, we will now be able to explore the Brazilian market for these non-ibuprofen products."

Specialty Chemicals: The Problem Child


Capital Allocation & Project Pipeline

Mahajan: "We have already informed to the stock exchanges that management has decided to change that project into the multi-product plant and for Gabapentin we will produce only on the campaign-based basis and will not have a dedicated plant."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth10%–12% upside in toplineFY25
EBITDA margin12%–15% (target 14%–15%, but current market situation implies slight top and bottom line decrease)FY25
PAT marginAround 7%–8%FY25
Non-ibuprofen export shareIncrease to 25%–30% of non-ibuprofen segmentFY25
Paracetamol capacity expansion"Five-digit" capacity increaseFY25
Revenue aspiration₹3,000 crore from existing products onlyBy 2028
Specialty chemicals recoverySequential and gradual recoveryBy end of this year

Key Metrics

MetricQ4 FY24
Total income₹511 cr, vs ₹596 cr in Q4 FY23 and ₹529 cr in Q3 FY24
EBITDA₹58 cr, vs ₹104 cr in Q4 FY23 and ₹53 cr in Q3 FY24
EBITDA margin11.3%, down 620 bps YoY from 17.5%, up 130 bps QoQ
Net profit₹28 cr, vs ₹65 cr in Q4 FY23 and ₹23 cr in Q3 FY24
EBIT margin – Pharmaceutical segment13.22%
EBIT margin – Specialty Chemical segment0.48%
Full-year total income (FY24)₹2,163 cr, vs ₹2,243 cr in FY23
Full-year EBITDA (FY24)₹262 cr, vs ₹252 cr in FY23
Full-year EBITDA margin (FY24)12.1%, up 90 bps from 11.2% in FY23
Full-year net profit (FY24)₹135 cr, vs ₹140 cr in FY23
Full-year exports (FY24)₹679 cr, grew 7% vs ₹634 cr in FY23
Full-year CAPEX (FY24)₹246 cr, vs ₹239 cr in FY23
Ibuprofen price range$10 to $11 per kg
Ibuprofen capacity utilization85% to 90%
Non-ibuprofen volume increase (FY24)10% to 15% in capacity terms for Paracetamol, Metformin, Clopidogrel
Metformin export growth (FY24)~60% increase from last year
Paracetamol export growth (FY24)10% increase
Paracetamol price decline (FY24)more than 35% to 40% during the year
Metformin price decline (FY24)20% to 22% during the year
Ethyl Acetate price decline (FY24)~10%
Revenue guidance (FY25)10% to 12% upside
EBITDA margin guidance (FY25)12% to 15%
PAT margin guidance (FY25)7% to 8%, vs ~6% in FY24
Gross margin guidance (FY25)20% to 25%
CAPEX guidance (FY25)₹150 cr to ₹200 cr, from internal accruals
Non-ibuprofen share of API portfolio (FY24)~40%
Non-ibuprofen export mix (current)20% export, 80% domestic; expected to reach 30% to 40% in FY25
R&D headcount125 people
R&D expenses7% to 8% of API segment revenue, expected to increase by 1% to 2%
Revenue aspiration (FY28)₹3,000 cr, from existing products, growing 12% to 13% annually